Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid‐positive individuals
Authors:
Open Access
- 1 December 2019
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 11 (1) , 679-689
Abstract
Introduction: Neurofilament light chain (NfL) is a promising blood biomarker to detect neurodegeneration in Alzheimer's disease (AD) and other brain disorders. However, there are limited reports of how longitudinal NfL relates to imaging biomarkers. We herein investigated the relationship between blood NfL and brain metabolism in AD.Methods: Voxelwise regression models tested the cross‐sectional association between [18F]fluorodeoxyglucose ([18F]FDG) and both plasma and cerebrospinal fluid NfL in cognitively impaired and unimpaired subjects. Linear mixed models were also used to test the longitudinal association between NfL and [18F]FDG in amyloid positive (Aβ+) and negative (Aβ−) subjects.Results: Higher concentrations of plasma and cerebrospinal fluid NfL were associated with reduced [18F]FDG uptake in correspondent brain regions. In Aβ+ participants, NfL associates with hypometabolism in AD‐vulnerable regions. Longitudinal changes in the association [18F]FDG‐NfL were confined to cognitively impaired Aβ+ individuals.Discussion: These findings indicate that plasma NfL is a proxy for neurodegeneration in AD‐related regions in Aβ+ subjects.Keywords
Funding Information
- Alzheimer's Disease Neuroimaging Initiative
- National Institutes of Health (U01 AG024904)
- U.S. Department of War
- U.S. Department of War (W81XWH‐12‐2‐0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Eisai
- Eli Lilly and Company
- Roche
- Genentech
- GE Healthcare
- H. Lundbeck A/S
- Meso Scale Diagnostics
- Novartis Pharmaceuticals Corporation
- Pfizer
- Servier
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- Biogen
- Canadian Institutes of Health Research (MOP‐11‐51‐31)
- Alzheimer's Association (NIRG‐08‐92090)
- Weston Brain Institute
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (0327/13‐1)
- Torsten Söderbergs Stiftelse
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88881.141186/2017‐01)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (460172/2014‐0)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (16/2551‐0000475‐7)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Vetenskapsrådet (2018‐02532)
This publication has 43 references indexed in Scilit:
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Alzheimer's Disease Neuroimaging Initiative (ADNI)Neurology, 2010
- Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-AnalysisAmerican Journal of Neuroradiology, 2008
- Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other DementiasJournal of Nuclear Medicine, 2008
- What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?Neurology, 2007
- Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical DementiaArchives of Neurology, 2006
- The Goteborg MCI study: mild cognitive impairment is a heterogeneous conditionJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Cortical Hypometabolism and its Recovery following Nucleus Basalis Lesions in Baboons: A PET StudyJournal of Cerebral Blood Flow & Metabolism, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Alzheimer's diseaseNeurology, 1983